Raymond Damadian
Damadian is the company's largest shareholder, with 8% of stock worth $6.5 million. Despite owning only 8% of the stock, he maintains almost 100% control of the company through a separate class of shares (Class C) that only Damadian controls 2007. Damadian later collaborated with Wilson Greatbatch, one early developer of the implantable pacemaker, to develop an MRI-compatible pacemaker. He invented a stand-up MRI system and has 15 MRI scanning centers across the United States. There are a number of independent MRI centers that use this technology both in the U.S. and around the world. The company conceived and built the world's first Upright Multi-Positional MRI, which was recognized as The Invention of the Year in 2007 by the Intellectual Properties Owners Association Education Foundation.
Nobel Prize controversies
The 2003 prize was awarded to Paul Lauterbur and Sir Peter Mansfield "for their discoveries concerning magnetic resonance imaging" (MRI). Two independent alternatives have been alleged. Raymond Damadian first reported that NMR could distinguish "in vitro" between cancerous and non-cancerous tissues on the basis of different proton relaxation times. He later translated this into the first human scan. Damadian's original report prompted Lauterbur to develop NMR into the present method. Damadian took out large advertisements in an international newspapers protesting his exclusion. Some researchers felt that Damadian's work deserved at least equal credit. Separately, Herman Y. Carr both pioneered the NMR gradient technique and demonstrated rudimentary MRI imaging in the 1950s. The Nobel prize winners had almost certainly seen Carr's work, but did not cite it. Consequently, the prize committee very likely was unaware of Carr's discoveries, a situation likely abetted by Damadian's campaign. Mansfield said in his autobiography that "the person who really missed out" the prize was Erwin Hahn for his contribution to the principles of spin echoes.